1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. WHO SHOULD READ THIS REPORT
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1 SECONDARY RESEARCH
1.4.2 DATA ANALYSIS FRAMEWORK
1.4.3 MARKET SIZE ESTIMATION
1.4.4 FORECASTING
1.4.5 PRIMARY RESEARCH AND DATA VALIDATION
2. EARLY TOXICITY TESTING MARKET – EXECUTIVE SUMMARY
2.1. MARKET SNAPSHOT, 2022 - 2030, MILLION USD
3. MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. MARKET DYNAMICS
3.2.1 DRIVERS
3.2.1.1. GROWTH IN RESEARCH AND DEVELOPMENT ACTIVITIES
3.2.1.2. GROWTH IN PREVALENCE OF CHRONIC DISEASES AND NEED FOR NEW TREATMENTS
3.2.2 RESTRAINTS
3.2.2.1. STRINGENT REGULATIONS
3.2.3 OPPORTUNITIES
3.2.3.1. DEVELOPMENT OF NEW TECHNOLOGIES
4. MARKET SHARE ANALYSIS
4.1. MARKET SHARE ANALYSIS OF TOP EARLY TOXICITY TESTING PROVIDERS, 2022
5. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
5.1. OVERVIEW
5.2. IN VIVO
5.2.1 IN VIVO MARKET, BY REGION
5.3. IN VITRO
5.3.1 GLOBAL IN VITRO MARKET, BY TECHNIQUE
5.3.1.1. CELL CULTURE MARKET, BY REGION
5.3.1.2. PCR MARKET, BY REGION
5.3.1.3. ELISA MARKET, BY REGION
5.3.1.4. WESTERN BLOTTING MARKET, BY REGION
5.3.1.5. PROTEIN BINDING ASSAYS MARKET, BY REGION
5.3.2 IN VITRO MARKET, BY REGION
5.4. IN SILICO
5.4.1 IN SILICO MARKET, BY REGION
6. GLOBAL EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
6.1. OVERVIEW
6.2. GENOTOXICITY
6.2.1 GENOTOXICITY MARKET, BY REGION
6.3. DERMAL TOXICITY
6.3.1 DERMAL TOXICITY MARKET, BY REGION
6.4. SKIN TOXICITY
6.4.1 SKIN TOXICITY MARKET, BY REGION
6.5. OCULAR TOXICITY
6.5.1 OCULAR TOXICITY MARKET, BY REGION
6.6. PHOTOTOXICITY
6.6.1 PHOTOTOXICITY MARKET, BY REGION
6.7. OTHERS
6.7.1 OTHERS MARKET, BY REGION
7. GLOBAL EARLY TOXICITY TESTING MARKET, BY END USER
7.1. OVERVIEW
7.2. PHARMACEUTICAL INDUSTRY
7.2.1 PHARMACEUTICAL INDUSTRY MARKET, BY REGION
7.3. COSMETIC INDUSTRY
7.3.1 COSMETIC INDUSTRY MARKET, BY REGION
7.4. CHEMICAL INDUSTRY
7.4.1 CHEMICAL INDUSTRY MARKET, BY REGION
7.5. FOOD INDUSTRY
7.5.1 FOOD INDUSTRY MARKET, BY REGION
7.6. OTHERS
7.6.1 OTHERS MARKET, BY REGION
8. GLOBAL EARLY TOXICITY TESTING MARKET, BY REGION
8.1. OVERVIEW
8.2. NORTH AMERICA
8.2.1 NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.2.1.1. NORTH AMERICA IN VITRO MARKET, BY TECHNIQUE
8.2.2 NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.2.3 NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER
8.2.4 NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY
8.2.4.1. U.S.
8.2.4.1.1. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.2.4.1.1.1. U.S. IN VITRO MARKET, BY TECHNIQUE
8.2.4.1.2. U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.2.4.1.3. U.S. EARLY TOXICITY TESTING MARKET, BY END USER
8.2.4.2. CANADA
8.2.4.2.1. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.2.4.2.1.1. CANADA IN VITRO MARKET, BY TECHNIQUE
8.2.4.2.2. CANADA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.2.4.2.3. CANADA EARLY TOXICITY TESTING MARKET, BY END USER
8.2.4.3. MEXICO
8.2.4.3.1. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.2.4.3.1.1. MEXICO IN VITRO MARKET, BY TECHNIQUE
8.2.4.3.2. MEXICO EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.2.4.3.3. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER
8.3. EUROPE
8.3.1 EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.1.1. EUROPE IN VITRO MARKET, BY TECHNIQUE
8.3.2 EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.3 EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4 EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY
8.3.4.1. UK
8.3.4.1.1. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.1.1.1. UK IN VITRO MARKET, BY TECHNIQUE
8.3.4.1.2. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.1.3. UK EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.2. GERMANY
8.3.4.2.1. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.2.1.1. GERMANY IN VITRO MARKET, BY TECHNIQUE
8.3.4.2.2. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.2.3. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.3. FRANCE
8.3.4.3.1. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.3.1.1. FRANCE IN VITRO MARKET, BY TECHNIQUE
8.3.4.3.2. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.3.3. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.4. ITALY
8.3.4.4.1. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.4.1.1. ITALY IN VITRO MARKET, BY TECHNIQUE
8.3.4.4.2. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.4.3. ITALY EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.5. SPAIN
8.3.4.5.1. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.5.1.1. SPAIN IN VITRO MARKET, BY TECHNIQUE
8.3.4.5.2. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.5.3. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.6. NETHERLANDS
8.3.4.6.1. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.6.1.1. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE
8.3.4.6.2. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.6.3. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.7. DENMARK
8.3.4.7.1. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.7.1.1. DENMARK IN VITRO MARKET, BY TECHNIQUE
8.3.4.7.2. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.7.3. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.8. FINLAND
8.3.4.8.1. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.8.1.1. FINLAND IN VITRO MARKET, BY TECHNIQUE
8.3.4.8.2. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.8.3. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.9. NORWAY
8.3.4.9.1. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.9.1.1. NORWAY IN VITRO MARKET, BY TECHNIQUE
8.3.4.9.2. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.9.3. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.10. SWEDEN
8.3.4.10.1. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.10.1.1. SWEDEN IN VITRO MARKET, BY TECHNIQUE
8.3.4.10.2. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.10.3. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.11. RUSSIA
8.3.4.11.1. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.11.1.1. RUSSIA IN VITRO MARKET, BY TECHNIQUE
8.3.4.11.2. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.11.3. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER
8.3.4.12. REST OF EUROPE
8.3.4.12.1. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.3.4.12.1.1. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE
8.3.4.12.2. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.3.4.12.3. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
8.4. ASIA-PACIFIC
8.4.1 ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.1.1. ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE
8.4.2 ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.3 ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4 ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY
8.4.4.1. AUSTRALIA
8.4.4.1.1. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.1.1.1. AUSTRALIA IN VITRO MARKET, BY TECHNIQUE
8.4.4.1.2. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.1.3. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4.2. CHINA
8.4.4.2.1. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.2.1.1. CHINA IN VITRO MARKET, BY TECHNIQUE
8.4.4.2.2. CHINA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.2.3. CHINA EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4.3. INDIA
8.4.4.3.1. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.3.1.1. INDIA IN VITRO MARKET, BY TECHNIQUE
8.4.4.3.2. INDIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.3.3. INDIA EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4.4. INDONESIA
8.4.4.4.1. INDONESIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.4.1.1. INDONESIA IN VITRO MARKET, BY TECHNIQUE
8.4.4.4.2. INDONESIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.4.3. INDONESIA EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4.5. JAPAN
8.4.4.5.1. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.5.1.1. JAPAN IN VITRO MARKET, BY TECHNIQUE
8.4.4.5.2. JAPAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.5.3. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4.6. SINGAPORE
8.4.4.6.1. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.6.1.1. SINGAPORE IN VITRO MARKET, BY TECHNIQUE
8.4.4.6.2. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.6.3. SINGAPORE EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4.7. SOUTH KOREA
8.4.4.7.1. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.7.1.1. SOUTH KOREA IN VITRO MARKET, BY TECHNIQUE
8.4.4.7.2. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.7.3. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4.8. TAIWAN
8.4.4.8.1. TAIWAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.8.1.1. TAIWAN IN VITRO MARKET, BY TECHNIQUE
8.4.4.8.2. TAIWAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.8.3. TAIWAN EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4.9. THAILAND
8.4.4.9.1. THAILAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.9.1.1. THAILAND IN VITRO MARKET, BY TECHNIQUE
8.4.4.9.2. THAILAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.9.3. THAILAND EARLY TOXICITY TESTING MARKET, BY END USER
8.4.4.10. REST OF ASIA-PACIFIC
8.4.4.10.1. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.4.4.10.1.1. REST OF ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE
8.4.4.10.2. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.4.4.10.3. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER
8.5. REST OF WORLD
8.5.1 REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.5.1.1. REST OF WORLD IN VITRO MARKET, BY TECHNIQUE
8.5.2 REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.5.3 REST OF WORLD EARLY TOXICITY TESTING MARKET, BY END USER
8.5.4 REST OF WORLD EARLY TOXICITY TESTING MARKET, BY COUNTRY
8.5.4.1. LATIN AMERICA
8.5.4.1.1. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.5.4.1.1.1. LATIN AMERICA IN VITRO MARKET, BY TECHNIQUE
8.5.4.1.2. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.5.4.1.3. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY END USER
8.5.4.2. MIDDLE EAST
8.5.4.2.1. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.5.4.2.1.1. MIDDLE EAST IN VITRO MARKET, BY TECHNIQUE
8.5.4.2.2. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.5.4.2.3. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY END USER
8.5.4.3. AFRICA
8.5.4.3.1. AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
8.5.4.3.1.1. AFRICA IN VITRO MARKET, BY TECHNIQUE
8.5.4.3.2. AFRICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS
8.5.4.3.3. AFRICA EARLY TOXICITY TESTING MARKET, BY END USER
9. COMPANY PROFILES
9.1. INOTIV INC.
9.1.1 COMPANY OVERVIEW
9.1.2 COMPANY SNAPSHOT
9.1.3 OPERATING BUSINESS SEGMENTS
9.1.4 PRODUCT PORTFOLIO
9.1.5 BUSINESS PERFORMANCE
9.1.6 SALES BY BUSINESS SEGMENT
9.1.7 SALES BY GEOGRAPHIC SEGMENT
9.1.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.1.9 PRIMARY MARKET COMPETITORS
9.2. BIO-RAD LABORATORIES INC
9.2.1 COMPANY OVERVIEW
9.2.2 COMPANY SNAPSHOT
9.2.3 OPERATING BUSINESS SEGMENTS
9.2.4 PRODUCT PORTFOLIO
9.2.5 BUSINESS PERFORMANCE
9.2.6 SALES BY BUSINESS SEGMENT
9.2.7 SALES BY GEOGRAPHIC SEGMENT
9.2.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.2.9 PRIMARY MARKET COMPETITORS
9.3. EVOTEC A.G.
9.3.1 COMPANY OVERVIEW
9.3.2 COMPANY SNAPSHOT
9.3.3 OPERATING BUSINESS SEGMENTS
9.3.4 PRODUCT PORTFOLIO
9.3.5 BUSINESS PERFORMANCE
9.3.6 SALES BY BUSINESS SEGMENT
9.3.7 SALES BY GEOGRAPHIC SEGMENT
9.3.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.3.9 PRIMARY MARKET COMPETITORS
9.4. AGILENT TECHNOLOGIES INC
9.4.1 COMPANY OVERVIEW
9.4.2 COMPANY SNAPSHOT
9.4.3 OPERATING BUSINESS SEGMENT
9.4.4 PRODUCT PORTFOLIO
9.4.5 BUSINESS PERFORMANCE
9.4.6 SALES BY BUSINESS SEGMENT
9.4.7 SALES BY GEOGRAPHIC SEGMENT
9.4.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.4.9 PRIMARY MARKET COMPETITORS
9.5. WUXI APPTEC
9.5.1 COMPANY OVERVIEW
9.5.2 COMPANY SNAPSHOT
9.5.3 OPERATING BUSINESS SEGMENTS
9.5.4 PRODUCT PORTFOLIO
9.5.5 BUSINESS PERFORMANCE
9.5.6 SALES BY BUSINESS SEGMENT
9.5.7 SALES BY GEOGRAPHIC SEGMENT
9.5.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.5.9 PRIMARY MARKET COMPETITORS
9.6. BRUKER
9.7.1 COMPANY OVERVIEW
9.7.2 COMPANY SNAPSHOT
9.7.3 OPERATING BUSINESS SEGMENT
9.7.4 PRODUCT PORTFOLIO
9.7.5 BUSINESS PERFORMANCE
9.7.6 SALES BY BUSINESS SEGMENT
9.7.7 SALES BY GEOGRAPHIC SEGMENT
9.7.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.7.9 PRIMARY MARKET COMPETITORS
9.7. PERKINELMER INC.
9.8.1 COMPANY OVERVIEW
9.8.2 COMPANY SNAPSHOT
9.8.3 OPERATING BUSINESS SEGMENT
9.8.4 PRODUCT PORTFOLIO
9.8.5 BUSINESS PERFORMANCE
9.8.6 SALES BY BUSINESS SEGMENT
9.8.7 SALES BY GEOGRAPHIC SEGMENT
9.8.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.8.9 PRIMARY MARKET COMPETITORS
9.8. ENZO BIOCHEM INC.
9.9.1 COMPANY OVERVIEW
9.9.2 COMPANY SNAPSHOT
9.9.3 OPERATING BUSINESS SEGMENT
9.9.4 PRODUCT PORTFOLIO
9.9.5 BUSINESS PERFORMANCE
9.9.6 SALES BY BUSINESS SEGMENT
9.9.7 SALES BY GEOGRAPHIC SEGMENT
9.9.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.9.9 PRIMARY MARKET COMPETITORS
9.9. DANAHER CORPORATION
9.10.1 COMPANY OVERVIEW
9.10.2 COMPANY SNAPSHOT
9.10.3 OPERATING BUSINESS SEGMENTS
9.10.4 PRODUCT PORTFOLIO
9.10.5 BUSINESS PERFORMANCE
9.10.6 SALES BY BUSINESS SEGMENT
9.10.7 KEY STRATEGIC MOVES & DEVELOPMENTS
9.10.8 PRIMARY MARKET COMPETITORS
9.10. EUROFINS SCIENTIFIC SE
9.11.1 COMPANY OVERVIEW
9.11.2 COMPANY SNAPSHOT
9.11.3 PRODUCT PORTFOLIO
9.11.4 BUSINESS PERFORMANCE
9.11.5 SALES BY GEOGRAPHIC SEGMENT
9.11.6 KEY STRATEGIC MOVES & DEVELOPMENTS
9.11.7 PRIMARY MARKET COMPETITORS
9.11. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
9.12.1 COMPANY OVERVIEW
9.12.2 COMPANY SNAPSHOT
9.12.3 OPERATING BUSINESS SEGMENTS
9.12.4 PRODUCT PORTFOLIO
9.12.5 BUSINESS PERFORMANCE
9.12.6 SALES BY BUSINESS SEGMENT
9.12.7 SALES BY GEOGRAPHIC SEGMENT
9.12.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.12.9 PRIMARY MARKET COMPETITORS
9.12. LABCORP DRUG DEVELOPMENT.
9.13.1 COMPANY OVERVIEW
9.13.2 COMPANY SNAPSHOT
9.13.3 OPERATING BUSINESS SEGMENTS
9.13.4 PRODUCT PORTFOLIO
9.13.5 BUSINESS PERFORMANCE
9.13.6 SALES BY BUSINESS SEGMENT
9.13.7 SALES BY GEOGRAPHIC SEGMENT
9.13.8 KEY STRATEGIC MOVES & DEVELOPMENTS
9.13.9 PRIMARY MARKET COMPETITORS
9.13. PROMEGA CORPORATION
9.14.1 COMPANY OVERVIEW
9.14.2 COMPANY SNAPSHOT
9.14.3 PRODUCT PORTFOLIO
9.14.4 KEY STRATEGIC MOVES & DEVELOPMENTS
9.14.5 PROMEGA CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS
9.14.6 PRIMARY MARKET COMPETITORS
9.14. INSPHERO AG
9.15.1 COMPANY OVERVIEW
9.15.2 COMPANY SNAPSHOT
9.15.3 PRODUCT PORTFOLIO
9.15.4 KEY STRATEGIC MOVES & DEVELOPMENTS
9.15.5 INSPHERO AG: KEY STRATEGIC MOVES & DEVELOPMENTS
9.15.6 PRIMARY MARKET COMPETITORS
LIST OF TABLES
TABLE 1. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 2. IN VIVO MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 3. GLOBAL IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 4. CELL CULTURE MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 5. PCR MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 6. ELISA MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 7. WESTERN BLOTTING MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 8. PROTEIN BINDING ASSAYS MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 9. IN VITRO MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 10. IN SILICO MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 11. GLOBAL EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 12. GENOTOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 13. DERMAL TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 14. SKIN TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 15. OCULAR TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 16. PHOTOTOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 17. OTHERS MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 18. GLOBAL EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 19. PHARMACEUTICAL INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 20. COSMETIC INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 21. CHEMICAL INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 22. FOOD INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 23. OTHERS MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 24. GLOBAL EARLY TOXICITY TESTING MARKET, BY REGION, 2022-2030, MILLION USD
TABLE 25. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 26. NORTH AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 27. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 28. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 29. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
TABLE 30. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 31. U.S. IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 32. U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 33. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 34. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 35. CANADA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 36. CANADA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 37. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 38. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 39. MEXICO IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 40. MEXICO EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 41. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 42. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 43. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 44. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 45. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 46. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
TABLE 47. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 48. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 49. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 50. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 51. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 52. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 53. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 54. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 55. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 56. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 57. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 58. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 59. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 60. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 61. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 62. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 63. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 64. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 65. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 66. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 67. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 68. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 69. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 70. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 71. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 72. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 73. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 74. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 75. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 76. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 77. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 78. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 79. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 80. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 81. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 82. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 83. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 84. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 85. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 86. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 87. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 88. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 89. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 90. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 91. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 92. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 93. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 94. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 95. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 96. ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 97. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 98. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 99. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
TABLE 100. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 101. AUSTRALIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 102. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 103. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 104. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 105. CHINA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 106. CHINA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 107. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 108. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 109. INDIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 110. INDIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 111. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 112. INDONESIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 113. INDONESIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 114. INDONESIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 115. INDONESIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 116. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 117. JAPAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 118. JAPAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 119. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 120. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 121. SINGAPORE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 122. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 123. SINGAPORE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 124. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 125. SOUTH KOREA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 126. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 127. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 128. TAIWAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 129. TAIWAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 130. TAIWAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 131. TAIWAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 132. THAILAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 133. THAILAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 134. THAILAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 135. THAILAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 136. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 137. REST OF ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 138. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 139. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 140. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 141. REST OF WORLD IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 142. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 143. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 144. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
TABLE 145. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 146. LATIN AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 147. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 148. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 149. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 150. MIDDLE EAST IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 151. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 152. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 153. AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 154. AFRICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 155. AFRICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 156. AFRICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 157. INOTIV INC.: COMPANY SNAPSHOT
TABLE 158. INOTIV INC: OPERATING SEGMENTS
TABLE 159. INOTIV INC.: PR0DUCT PORTFOLIO
TABLE 160. INOTIV INC.: BUSINESS SEGMENT
TABLE 161. INOTIV INC.: GEOGRAPHIC SEGMENT
TABLE 162. INOTIV INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 163. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
TABLE 164. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS
TABLE 165. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO
TABLE 166. BIO-RAD LABORATORIES INC: BUSINESS SEGMENT
TABLE 167. BIO-RAD LABORATORIES INC: GEOGRAPHIC SEGMENT
TABLE 168. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 169. EVOTEC A.G.: COMPANY SNAPSHOT
TABLE 170. EVOTEC A.G.: OPERATING SEGMENTS
TABLE 171. EVOTEC A.G.: PRODUCT PORTFOLIO
TABLE 172. EVOTEC A.G.: BUSINESS SEGMENT
TABLE 173. EVOTEC A.G.: GEOGRAPHIC SEGMENT
TABLE 174. EVOTEC A.G.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 175. AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT
TABLE 176. AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS
TABLE 177. AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO
TABLE 178. AGILENT TECHNOLOGIES INC: BUSINESS SEGMENT
TABLE 179. AGILENT TECHNOLOGIES INC: GEOGRAPHIC SEGMENT
TABLE 180. AGILENT TECHNOLOGIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 181. WUXI APPTEC.: COMPANY SNAPSHOT
TABLE 182. WUXI APPTEC: OPERATING SEGMENTS
TABLE 183. WUXI APPTEC.: PR0DUCT PORTFOLIO
TABLE 184. WUXI APPTEC.: BUSINESS SEGMENT
TABLE 185. WUXI APPTEC.: GEOGRAPHIC SEGMENT
TABLE 186. WUXI APPTEC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 187. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 188. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 189. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 190. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT
TABLE 191. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT
TABLE 192. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 193. BRUKER: COMPANY SNAPSHOT
TABLE 194. BRUKER: OPERATING SEGMENTS
TABLE 195. BRUKER: PRODUCT PORTFOLIO
TABLE 196. BRUKER: BUSINESS SEGMENT
TABLE 197. BRUKER: GEOGRAPHIC SEGMENT
TABLE 198. BRUKER: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 199. PERKINELMER INC.: COMPANY SNAPSHOT
TABLE 200. PERKINELMER INC.: OPERATING SEGMENTS
TABLE 201. PERKINELMER INC.: PRODUCT PORTFOLIO
TABLE 202. PERKINELMER INC.: BUSINESS SEGMENT
TABLE 203. PERKINELMER INC.: GEOGRAPHIC SEGMENT
TABLE 204. PERKINELMER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 205. ENZO BIOCHEM INC.: COMPANY SNAPSHOT
TABLE 206. ENZO BIOCHEM INC.: OPERATING SEGMENTS
TABLE 207. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO
TABLE 208. ENZO BIOCHEM INC.: BUSINESS SEGMENT
TABLE 209. ENZO BIOCHEM INC.: GEOGRAPHIC SEGMENT
TABLE 210. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 211. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 212. DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 213. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 214. DANAHER CORPORATION: BUSINESS SEGMENT
TABLE 215. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 216. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT
TABLE 217. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO
TABLE 218. EUROFINS SCIENTIFIC SE: GEOGRAPHIC SEGMENT
TABLE 219. EUROFINS SCIENTIFIC SE: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 220. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
TABLE 221. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS
TABLE 222. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
TABLE 223. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS SEGMENT
TABLE 224. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: GEOGRAPHIC SEGMENT
TABLE 225. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 226. LABCORP DRUG DEVELOPMENT.: COMPANY SNAPSHOT
TABLE 227. LABCORP DRUG DEVELOPMENT.: OPERATING SEGMENTS
TABLE 228. LABCORP DRUG DEVELOPMENT.: PRODUCT PORTFOLIO
TABLE 229. LABCORP DRUG DEVELOPMENT.: BUSINESS SEGMENT
TABLE 230. LABCORP DRUG DEVELOPMENT.: GEOGRAPHIC SEGMENT
TABLE 231. LABCORP DRUG DEVELOPMENT.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 232. PROMEGA CORPORATION: COMPANY SNAPSHOT
TABLE 233. PROMEGA CORPORATION: PRODUCT PORTFOLIO
TABLE 234. INSPHERO AG: COMPANY SNAPSHOT
TABLE 235. INSPHERO AG: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. MARKET SHARE ANALYSIS OF TOP EARLY TOXICITY TESTING PROVIDERS, 2022
FIGURE 2. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 3. IN VIVO MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 4. GLOBAL IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 5. CELL CULTURE MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 6. PCR MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 7. ELISA MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 8. WESTERN BLOTTING MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 9. PROTEIN BINDING ASSAYS MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 10. IN VITRO MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 11. IN SILICO MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 12. GLOBAL EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 13. GENOTOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 14. DERMAL TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 15. SKIN TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 16. OCULAR TOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 17. PHOTOTOXICITY MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 18. OTHERS MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 19. GLOBAL EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 20. PHARMACEUTICAL INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 21. COSMETIC INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 22. CHEMICAL INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 23. FOOD INDUSTRY MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 24. OTHERS MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 25. GLOBAL EARLY TOXICITY TESTING MARKET, BY REGION, 2022-2030, MILLION USD
FIGURE 26. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 27. NORTH AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 28. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 29. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 30. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 31. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 32. U.S. IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 33. U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 34. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 35. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 36. CANADA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 37. CANADA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 38. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 39. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 40. MEXICO IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 41. MEXICO EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 42. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 43. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 44. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 45. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 46. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 47. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 48. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 49. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 50. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 51. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 52. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 53. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 54. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 55. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 56. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 57. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 58. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 59. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 60. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 61. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 62. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 63. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 64. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 65. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 66. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 67. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 68. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 69. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 70. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 71. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 72. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 73. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 74. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 75. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 76. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 77. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 78. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 79. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 80. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 81. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 82. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 83. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 84. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 85. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 86. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 87. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 88. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 89. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 90. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 91. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 92. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 93. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 94. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 95. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 96. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 97. ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 98. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 99. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 100. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 101. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 102. AUSTRALIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 103. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 104. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 105. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 106. CHINA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 107. CHINA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 108. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 109. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 110. INDIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 111. INDIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 112. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 113. INDONESIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 114. INDONESIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 115. INDONESIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 116. INDONESIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 117. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 118. JAPAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 119. JAPAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 120. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 121. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 122. SINGAPORE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 123. SINGAPORE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 124. SINGAPORE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 125. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 126. SOUTH KOREA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 127. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 128. SOUTH KOREA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 129. TAIWAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 130. TAIWAN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 131. TAIWAN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 132. TAIWAN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 133. THAILAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 134. THAILAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 135. THAILAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 136. THAILAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 137. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 138. REST OF ASIA-PACIFIC IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 139. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 140. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 141. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 142. REST OF WORLD IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 143. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 144. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 145. REST OF WORLD EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD
FIGURE 146. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 147. LATIN AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 148. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 149. LATIN AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 150. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 151. MIDDLE EAST IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 152. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 153. MIDDLE EAST EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 154. AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 155. AFRICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 156. AFRICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 157. AFRICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 158. INOTIV INC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 159. INOTIV INC: PRIMARY MARKET COMPETITORS
FIGURE 160. BIO-RAD LABORATORIES INC CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 161. BIO-RAD LABORATORIES INC: PRIMARY MARKET COMPETITORS
FIGURE 162. EVOTEC A.G.: NET SALES, 2019–2021 ($MILLION)
FIGURE 163. EVOTEC A.G.: PRIMARY MARKET COMPETITORS
FIGURE 164. AGILENT TECHNOLOGIES INC: NET SALES, 2020–2022 ($MILLION)
FIGURE 165. AGILENT TECHNOLOGIES INC: PRIMARY MARKET COMPETITORS
FIGURE 166. WUXI APPTEC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 167. WUXI APPTEC: PRIMARY MARKET COMPETITORS
FIGURE 168. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)
FIGURE 169. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS
FIGURE 170. BRUKER: NET SALES, 2019–2021 ($MILLION)
FIGURE 171. BRUKER: PRIMARY MARKET COMPETITORS
FIGURE 172. PERKINELMER INC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 173. PERKINELMER INC.: PRIMARY MARKET COMPETITORS
FIGURE 174. ENZO BIOCHEM INC.: NET SALES, 2019–2021 ($MILLION)
FIGURE 175. ENZO BIOCHEM INC.: PRIMARY MARKET COMPETITORS
FIGURE 176. DANAHER CORPORATION: NET SALES, 2020–2022 ($MILLION)
FIGURE 177. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 178. EUROFINS SCIENTIFIC SE CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 179. EUROFINS SCIENTIFIC SE: PRIMARY MARKET COMPETITORS
FIGURE 180. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 181. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRIMARY MARKET COMPETITORS
FIGURE 182. LABCORP DRUG DEVELOPMENT. CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 183. LABCORP DRUG DEVELOPMENT.: PRIMARY MARKET COMPETITORS
FIGURE 184. PROMEGA CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 185. INSPHERO AG: PRIMARY MARKET COMPETITORS